The report found that the proliferation of omega-3 fatty acids in the active pharmaceutical ingredient (API) market, increasing awareness of chronic diseases, expanding the scope of omega-3 fatty acids and regulations governing the use of Omega-3 in infant formulas favor, just a few are examples that support this market growth.
Advances in technology are a major contributor to market growth.
According to the Fortune Business Insights report, “One of the main drivers of the growth of the omega-3 fatty acids market has been the continuous technological advancement that improves the way these substances are released and absorbed by the body. The development of lipid-based nutritional supplements remains a challenging endeavor because of their unpredictable absorption rate and bioavailability. Various studies suggest that various factors can limit the absorption of these types of fatty acids in the body. “
Managers invest in research
“The major players in the market are investing large amounts of capital in research and development integrating technologies that will improve the bioavailability of omega-3s in the body,” the report said. “For example, in October 2019 Pharmako Biotechnologies launched a new self-emulsifying drug delivery system from Aquacelle that increases oral omega-3 absorption six times compared to standard fish oil.”
Eric Meppem, commercial director and co-founder of Pharmako Biotechnologies, said bioavailability plays two important roles in the omega-3 market.
“First, from an efficacy point of view, it improves results and the way omega-3s are supplemented. By improving the absorption of omega-3s in the blood, products become more effective, meaning consumers are more likely to get the correct dose. Pharmako Biotechnologies manufactures AquaCelle formulations, which are patent-pending, clinically validated self-microemulsifying drug delivery systems (SMEDDS) that have been specially developed to increase the bioavailability of lipophilic active ingredients. “
“Second, improving the bioavailability of omega-3 fatty acids means more sustainable use of resources,” Meppem continues. “Addressing this key challenge of the sustainability of fish and other marine resources is critical to the continued viability of the segment. This is also a major problem for many consumers. “
Meppem said achieving bioavailability is one thing, communicating it to consumers is another. “Consumers who take omega-3 supplements are not unfamiliar with absorption or bioavailability. Many became aware of the concept a few years ago when krill oil entered the segment. Unfortunately, brand companies in several international markets were not communicating or explaining this concept very well at the time. To explain this, companies need to keep it simple and support claims with human pharmacokinetic studies. “
Meppem told NutraIngredients-USA that Pharmako is explaining the concept to new customers by demonstrating fish oil in a beaker or glass of water and comparing it to AquaCelle fish oil in a similar water vessel. “By showing how AquaCelle microemulsifies itself, people can tell the difference in how the fish oil is absorbed in the aqueous environment of the human gastrointestinal tract.”
AquaCelle’s six-time absorption system was demonstrated in a Pharmako-funded human pharmacokinetic study conducted at the University of Queensland and published in the European Journal of Nutrition.
Growing consumer awareness of the health benefits of omega-3s, especially polyunsaturated fatty acids, is fueling the global market. The increased focus on preventive healthcare is a major driver for the market as well as new benefits being discovered.
“New studies are being published on the new benefits of supplementing with omega-3 fatty acids,” said Meppem. “This includes more studies and emerging research on segments besides traditional cardiovascular and joint health segments, such as cognitive health and brain health, and even protecting the brain from impacts in contact sports.”
The global omega-3 fatty acids market size was US $ 1.45 billion in 2019 and is projected to reach US $ 1.92 billion by 2027, a CAGR of 3.89% over the forecast period 2020-2027.
Meppem also assumes that the omega-3 dietary supplement segment will continue to grow. “Especially since many brands are now offering more efficient and easier-to-take products based on novel delivery systems. Not only will these new offerings benefit consumers and the environment, but they will also bring better margins back to a segment that has been marketed in almost every market in the world. “
Latest in omega-3 research
To learn more about the latest research on omega-3 fatty acids, visit NutraIngredients-USA’s free webinar schedule for September 24th at 11:30 am local time. The event will be attended by an all-star panel made up of Dr. William S. Harris of the University of South Dakota, Dr. Philip Calder from the University of Southampton in the UK and Dr. Jeffry Bland of the Personalized Lifestyle Medicine Institute. For more information and to register, visit the event Homepage.